Document is current

Article History

Received: 7 July 2025

Accepted: 4 September 2025

First Online: 16 October 2025

Declarations

:

: Ethics approval was granted by the Health and Social Care Research Ethics Committee A (HSC REC A) [23/NI/0156]. All patients provided written consent. Clinicians indicated their willingness to participate through tacit consent, confirmed by email and through completion of the Delphi surveys. All participants were informed of their right to withdraw from the study at any point.

: Not applicable.

: CL has acted as a speaker for Boehringer Ingelheim. KK has acted as a consultant, speaker or received grants for investigator-initiated studies for Astra Zeneca, Bayer, Novo Nordisk, Sanofi-Aventis, Servier, Lilly and Merck Sharp & Dohme, Boehringer Ingelheim, Oramed Pharmaceuticals, Pfizer, Roche, Daiichi-Sankyo, Applied Therapeutics, Embecta and Nestle Health Science. CAM has participated on advisory boards/consulted for AstraZeneca, Boehringer Ingelheim and Lilly Alliance, Novartis and PureTech Health, serves as an advisor for HAYA Therapeutics, has received speaker fees from AstraZeneca, Boehringer Ingelheim and Novo Nordisk, conference attendance support from AstraZeneca, and research support from Amicus Therapeutics, AstraZeneca, Guerbet Laboratories Limited, Roche and Univar Solutions B.V.